Literature DB >> 15339327

Helicobacter pylori infection prevents the occurrence of the tolerance phenomenon of histamine H2 receptor antagonists.

T Fujisawa1, K Adachi, Y Komazawa, T Mihara, T Azumi, T Katsube, K Furuta, H Kazumori, Y Kinoshita.   

Abstract

BACKGROUND: The attenuated anti-secretory activity of H2 receptor antagonists (H2RA) during continuous administration is referred to as the tolerance phenomenon. However, it is not clarified whether Helicobacter pylori infection affects the occurrence of tolerance to H2RA. It is also not clarified whether the tolerance phenomenon occurs to a new H2RA, lafutidine. AIM: To investigate the occurrence of the tolerance phenomenon in subjects with and without H. pylori infection during the continuous administration of lafutidine and famotidine. SUBJECTS AND METHODS: Subjects were 20 healthy male volunteers (seven H. pylori positive and 13 H. pylori negative cases). All subjects were examined by ambulatory intragastric pH monitoring five times without medication, on the first and 15th day of the administration of 20 mg b.d. famotidine and 10 mg b.d. lafutidine in a cross-over fashion.
RESULTS: The tolerance phenomenon was not observed in H. pylori-positive subjects during the 15-day-long administration of both H2RAs. In contrast, the tolerance phenomenon was observed in H. pylori negative subjects, which has been previously reported.
CONCLUSIONS: This study demonstrated that H. pylori infection affects the tolerance phenomenon during continuous administration of H2RAs. Copyright 2004 Blackwell Publishing Ltd

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339327     DOI: 10.1111/j.1365-2036.2004.02147.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  10 in total

1.  Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia.

Authors:  Yoshikazu Kinoshita; Shunji Ishihara
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

2.  Burden and cost of treatment for GERD.

Authors:  Yoshikazu Kinoshita; Shuichi Sato
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

3.  Which has superior acid-suppressive effect, 10 mg omeprazole once daily or 20 mg famotidine twice daily? Effects of single or repeated administration in Japanese Helicobacter pylori-negative CYP2C19 extensive metabolizers.

Authors:  Tomohiko Shimatani; Masaki Inoue; Tomoko Kuroiwa; Mutsuko Moriwaki; Jing Xu; Kazuro Ikawa; Norifumi Morikawa; Susumu Tazuma
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

4.  Improvement in symptoms after H2-receptor antagonist-based therapy for eradication of H pylori infection.

Authors:  Takeshi Hagiwara; Mototsugu Kato; Tomonori Anbo; Akimichi Imamura; Toshihiro Suga; Takumi Uchida; Akira Fujinaga; Manabu Nakagawa; Soichi Nakagawa; Yuichi Shimizu; Jyunji Yamamoto; Hiroshi Takeda; Masahiro Asaka
Journal:  World J Gastroenterol       Date:  2007-07-28       Impact factor: 5.742

5.  Comparison of PPIs and H2-receptor antagonists plus prokinetics for dysmotility-like dyspepsia.

Authors:  Masahiro Sakaguchi; Miyuki Takao; Yasuo Ohyama; Hiroshi Oka; Hiroshi Yamashita; Takumi Fukuchi; Kiyoshi Ashida; Masahiro Murotani; Masuyo Murotani; Kazuo Majima; Hiroshi Morikawa; Takashi Hashimoto; Keisuke Kiyota; Hirohiko Esaki; Kanji Amemoto; Gouhei Isowa; Fumiyuki Takao
Journal:  World J Gastroenterol       Date:  2012-04-07       Impact factor: 5.742

6.  Stronger inhibition of gastric acid secretion by lafutidine, a novel H2 receptor antagonist, than by the proton pump inhibitor lansoprazole.

Authors:  Hatsushi Yamagishi; Tomoyuki Koike; Shuichi Ohara; Toru Horii; Ryousuke Kikuchi; Shigeyuki Kobayashi; Yasuhiko Abe; Katsunori Iijima; Akira Imatani; Kaori Suzuki; Takanori Hishinuma; Junichi Goto; Tooru Shimosegawa
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

7.  Heartburn issues burnt out?

Authors:  Kentaro Sugano
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 6.772

8.  Lafutidine 10 mg versus Rabeprazole 20 mg in the Treatment of Patients with Heartburn-Dominant Uninvestigated Dyspepsia: A Randomized, Multicentric Trial.

Authors:  Bhupesh Dewan; Nisha Philipose
Journal:  Gastroenterol Res Pract       Date:  2011-05-05       Impact factor: 2.260

Review 9.  Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use.

Authors:  Yoshikazu Kinoshita; Norihisa Ishimura; Shunji Ishihara
Journal:  J Neurogastroenterol Motil       Date:  2018-04-30       Impact factor: 4.924

10.  A comparison between the combined effect of calcium carbonate with sucroferric oxyhydroxide and other phosphate binders: an in vitro and in vivo experimental study.

Authors:  Atsushi Yaguchi; Kenji Akahane; Kumi Tsuchioka; Saori Yonekubo; Shota Yamamoto; Yasuaki Tamai; Satoshi Tatemichi; Hiroo Takeda
Journal:  BMC Nephrol       Date:  2019-12-12       Impact factor: 2.388

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.